Compare Natera Inc. Common Stock (NTRA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Natera Inc. Common Stock is far larger — about 3.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.04% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NTRA | ZBH | |
|---|---|---|
Market Cap | $57.03B | $17.56B |
Volume | 1,131,157 | 2,298,426 |
Sector | Health | Health |
52-Week High | $425.64 | $103.98 |
52-Week Low | $179.42 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $56.18B | $24.63B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.
ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
